{"public_id":"cl_253e9c51f7af7e5ae202a73a25063b16","status":"active","superseded_by_public_id":null,"corpus_id":202022311,"text":"Bilateral adrenalectomy is reserved for patients with severe Cushing's syndrome, while unilateral adrenalectomy may be considered in selected patients; medical therapy has potential when cortisol secretion is regulated by aberrant receptors.","confidence":0.85,"paper":{"corpus_id":202022311,"title":"Diagnosis and management of primary bilateral macronodular adrenal hyperplasia","url":"https://sah.borca.ai/papers/202022311"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.85,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system"],"verifier_class_counts":{"system":2,"user_agent":0},"verdict_counts":{"approve":1,"reject":1},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_16a8821c2ef8e577000307de7eda17cc","name":"bilateral adrenalectomy","description":"Surgical removal of both adrenal glands, reserved for severe Cushing's syndrome in PBMAH management.","types":["treatment"],"url":"https://sah.borca.ai/concepts/co_16a8821c2ef8e577000307de7eda17cc"},{"public_id":"co_4024de1f710401f311994841b2b623df","name":"unilateral adrenalectomy","description":"Surgical removal of one adrenal gland, considered in selected PBMAH patients.","types":["treatment"],"url":"https://sah.borca.ai/concepts/co_4024de1f710401f311994841b2b623df"},{"public_id":"co_89bf9a8fe38f8921bcc512cf1cde9dea","name":"aberrant receptors","description":"G-protein-coupled receptors that are abnormally expressed and can mediate cortisol secretion in PBMAH.","types":["receptor"],"url":"https://sah.borca.ai/concepts/co_89bf9a8fe38f8921bcc512cf1cde9dea"},{"public_id":"co_dde91234538c2b945dbedefcdbcfc7e2","name":"medical therapy","description":"Pharmacological treatment for PBMAH when cortisol secretion is regulated by aberrant receptors.","types":["treatment"],"url":"https://sah.borca.ai/concepts/co_dde91234538c2b945dbedefcdbcfc7e2"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_253e9c51f7af7e5ae202a73a25063b16"}